Abstract: A mold for producing a variety of fenestration members having different predetermined lengths is disclosed. Generally, the mold has a first lineal mold part that has an extended length and a second lineal mold part also having an extended length. The mold may also have mold end parts that are adapted to form end features of the fenestration member. In use, the first lineal mold part and the second lineal mold part fit together to define a profile. The first and second mold end parts can be positioned in a range of positions to define the lengths of a variety of different molded fenestration members.

Abstract: A mold for producing a variety of fenestration members having different predetermined lengths is disclosed. Generally, the mold has a first lineal mold part that has an extended length and a second lineal mold part also having an extended length. The mold may also have mold end parts that are adapted to form end features of the fenestration member. In use, the first lineal mold part and the second lineal mold part fit together to define a profile. The first and second mold end parts can be positioned in a range of positions to define the lengths of a variety of different molded fenestration members.

Abstract: A mold for producing a variety of fenestration members having different predetermined lengths is disclosed. Generally, the mold has a first lineal mold part that has an extended length and a second lineal mold part also having an extended length. The mold may also have mold end parts that are adapted to form end features of the fenestration member. In use, the first lineal mold part and the second lineal mold part fit together to define a profile. The first and second mold end parts can be positioned in a range of positions to define the lengths of a variety of different molded fenestration members.

Abstract: A window sash is formed from a pair of one-piece injection molded sash body members having substantially the same mechanical configuration. Each sash body member has an inner, facing surface and a non-facing surface. The facing surface of each sash body member is provided with a plurality of locators of two different types, arranged about axis of anti-symmetry. The two different types of locators are complementary to one another, and so are configured to engage each other. This allows a window sash to be formed of substantially identical components that are mated together. Each sash member may be provided, on its facing surface, with a weld wall that is set back from the outer sash member edges. The window sash may be assembled after heating the weld walls and joining the two substantially identical sash members.

Abstract: A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.

Abstract: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.

Abstract: A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.